Total Voting Rights

Alliance Pharma PLC

03 May 2023

 

For immediate release

03 May 2023

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Total Voting Rights

Alliance Pharma plc (AIM: APH), the international healthcare group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 30 April 2023 the Company's issued share capital consists of 540,030,264 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 540,030,264 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

Alliance Pharma plc	+ 44 (0)1249 466966
Cora McCallum, Head of Investor Relations & Corporate Communications	+ 44 (0)1249 705168
[e-mail]
Buchanan	+ 44 (0)20 7466 5000
Mark Court / Hannah Ratcliff
[e-mail]
Numis Securities Limited (Nominated Adviser and Corporate Broking)	+ 44 (0)20 7260 1000
Freddie Barnfield / Duncan Monteith / Sher Shah
Investec Bank plc	+ 44 (0)20 7597 5970
Corporate Broking: Patrick Robb

About Alliance

Alliance Pharma plc (AIM: APH) is a growing consumer healthcare company. Our purpose is to empower people to make a positive difference to their health and wellbeing by making our trusted and proven brands available around the world.

We deliver organic growth through investing in our priority brands and channels, in related innovation, and through selective geographic expansion to increase the reach of our brands. Periodically, we may look to enhance our organic growth through selective, complementary acquisitions.

Headquartered in the UK, the Group employs around 285 people based in locations across Europe, North America, and the Asia Pacific region. By outsourcing our manufacturing and logistics we remain asset-light and focused on maximising the value we can bring, both to our stakeholders and to our brands. For more information on Alliance, please visit our website: www.alliancepharmaceuticals.com

 

END